Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we examined how laquinimod promotes immune modulation. Oral laquini...

Full description

Bibliographic Details
Main Authors: Ulf Schulze-Topphoff, Aparna Shetty, Michel Varrin-Doyer, Nicolas Molnarfi, Sharon A Sagan, Raymond A Sobel, Patricia A Nelson, Scott S Zamvil
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3316495?pdf=render

Internet

http://europepmc.org/articles/PMC3316495?pdf=render

Similar Items